REGULATORY AUTHORITIES OF DIFFERENT COUNTRIES

-

REGULATORY AUTHORITIES OF DIFFERENT COUNTRIES

Various regulatory authorities in major developed and developing nations around the world, as well as the scope and issues these organizations face in delivering safe and effective healthcare goods.


USA  Food and Drug Administration (FDA)

Europe European Medicines Agency (EMEA)

UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Sweden Medical Products Agency (MPA)

Netherlands Medicines Evaluation Board

Ireland Irish Medicines Board

Italy Italian Pharmaceutical Agency

Denmark Danish Medicines Agency

Australia  Therapeutic Goods Administration (TGA) 

Japan Ministry of Health, Labor & Welfare(MHLW)

India  Central Drug Standard Control Organization (CDSCO)

Canada  Health Canada

Costa Rica Ministry of Health

Nigeria  National Agency for Food and Drug Administration and Control (NAFDAC)

Ukraine  Ministry of Health

Singapore Centre for Pharmaceutical Administration Health Sciences Authority

Hong Kong Department of Health: Pharmaceutical Services

Sweden Medical Products Agency (MPA)

Thailand  Ministry of Public Health - Thailand Food And Drug Administration (Thai FDA)

China National Medical Products Administration

Germany Federal Institute for Drugs and  Medical Devices

Malaysia National Pharmaceutical Control Bureau, Ministry of Health

Pakistan Drugs Control Organization, Ministry of Health

South Africa Medicines Control Council

Sri Lanka National Medicines Regulatory Authority

Switzerland Swiss medic  , Swiss Agency for Therapeutic Products

Uganda Uganda National Council for Science and Technology (UNCST)

Brazil Agencia Nacional de Vigiloncia Sanitaria (ANVISA )

Oman Directorate General of Pharmaceutical Affairs and Drug Control

Qatar Pharmacy and Drug Control Department

Saudi Arabia Saudi Food and Drug Authority (SFDA)

Jordan Jordan Food and Drug Administration

Bahrain National Health Regulatory Authority 

Egypt Egyptian Drug Authority (EDA)

Kuwait Kuwait drug and food control administration

UAE Ministry of Health and prevention



INTERNATIONAL ORGANIZATIONS

 

World Health Organization (WHO)

 

Pan American Health Organization (PAHO)

 

World Trade Organization (WTO)

 

International Conference on Harmonization (ICH)

 

World Intellectual Property Organization (WIPO)

Comments

Post a Comment

Popular posts from this blog

checklist for registration of IND as per ICH CTD format

-
 INTRODUCTION:  ABOUT ICH: “International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use”. This project brings together regulatory authorities of Europe, Japan & US, to discuss scientific & technical aspects of pharmaceutical product registration. ICH’s mission is to achieve greater harmonization worldwide to ensure that safe, effective, and high quality medicines are developed, and registered and maintained in the most resource-efficient manner while meeting high standards.1 ICH aims to provide uniform standards for technical requirements for pharmaceuticals for human use. They are developed by regulatory and pharma industry authorities. The purpose of ICH guidelines is to ensure safe, effective, and high-quality medicines are developed and registered efficiently. ABOUT CTD: CTD - Common Technical Document3 The agreement to assemble all the Quality, Safety, and Efficacy information in a common format called CTD has revolution...
Read more

New Drug Application(NDA)

-
Image
  New Drug Application It is an application filed with FDA, for a U.S. generic drug approval for an existing licensed medication or approved drug. In simple words, ―It is an application for the approval of Generic Drugs. A New Drug Application (NDA) is a comprehensive submission to the U.S. Food and Drug Administration (FDA) by a drug sponsor seeking approval to market a new drug in the United States. The NDA provides detailed information to the FDA to evaluate the safety, efficacy, labeling, and manufacturing standards of the new drug. It includes data from laboratory and animal preclinical studies as well as human clinical trials (Phase 1-4). The FDA reviews the NDA within 60 days of submission and issues one of three action letters: Approval Letter, Approvable Letter, or Not Approvable Letter The NDA's goals are to offer adequate material for FDA reviewers to make the following essential decisions: Whether the medicine is safe and effective in its intended application(s), and wh...
Read more